

## INFORMATION FOR AUTHORS

### EDITOR

Bruce H. Thiers, MD  
Medical University of South Carolina  
Charleston, SC

### DEPUTY EDITOR

Dirk M. Elston, MD  
Geisinger Medical Center  
Danville, PA

### PUBLISHER

Elsevier Inc.  
11830 Westline Industrial Dr  
St. Louis, MO 63146-3318  
Susan M. Kell, Senior Issue Manager  
Phone: 215-239-3380; fax: 215-239-3388  
E-mail: [s.kell@elsevier.com](mailto:s.kell@elsevier.com)

### EDITORIAL OFFICE

Melissa Derby, Managing Editor  
*Journal of the American Academy of Dermatology*  
482 Southbridge St  
Ste #266  
Auburn, MA 01501  
Phone: 508-476-2724; fax: 508-476-7479  
E-mail: [mderby@aad.org](mailto:mderby@aad.org)

All manuscripts must be submitted via the Elsevier Electronic System (EES) (<http://ees.elsevier.com/jaad>).

The Information for Authors undergoes continuous revision. The most current version can be found at [www.eblue.org](http://www.eblue.org). All manuscripts for the *Journal of the American Academy of Dermatology* must be submitted electronically through the Web-based EES program. EES may be accessed by visiting <http://ees.elsevier.com/jaad>. The site provides instructions for manuscript submission as well as a tutorial for authors. Word, WordPerfect, RTF, and Text files will be accepted; Word and WordPerfect are preferred. All tracking and follow-up will be done through EES (<http://ees.elsevier.com/jaad>). Questions about the program may be addressed to [mderby@aad.org](mailto:mderby@aad.org). All manuscript submissions must include the copyright transfer form, the conflict of interest disclosure form, the authorship statement (attestation) form, and the manuscript submission checklist. These forms can be copied from the January or July issues of the *Journal* and/or downloaded from either our Web site (<http://www.eblue.org>) or EES (<http://ees.elsevier.com/jaad>). Please scan the completed forms and upload them to EES with your submission. If this presents a problem, please contact Melissa Derby at [mderby@aad.org](mailto:mderby@aad.org).

**Editorial policies.** The *Journal of the American Academy of Dermatology* is a refereed journal designed to meet the continuing education needs of the Academy members and the international dermatologic community. The *Journal* bases its policies on the guidelines set forth by the International Committee of Medical Journal Editors (<http://www.icmje.org>).

**Disclaimer.** Statements and opinions expressed in the articles and communications herein are those of the author(s) and not necessarily those of the Editor(s), publisher, or Academy. The Editor(s), publisher, and Academy disclaim any responsibility or liability for such material and do not guarantee, warrant, or endorse any products or services advertised in this publication, nor do they guarantee any claim made by the manufacturer of such products or services.

**Conflict of interest.** The *Journal* requires all authors to acknowledge, in the comments section of EES (<http://ees.elsevier.com/jaad>), all funding sources that supported their work as well as all institutional or corporate affiliations of the authors. **The title page must also include a publishable statement disclosing any commercial associations, current and over the past 5 years, that might pose a conflict of interest.** These include but are not limited to employment, royalties, consultant arrangements with a commercial entity, stock or other equity ownership, stock options, patent licensing arrangements, payments for conducting or publicizing a product or study, or consulting relationships with investment companies. In addition, authors are required to disclose similar associations with companies that make a competing product. When no conflicting or competing interests are present, this should be indicated in the publishable disclosure statement. If the authors have competing or conflicting interests that cannot be disclosed in publishable statements, authors should list them in the comments section of EES (<http://ees.elsevier.com/jaad>). They should also explain these interests as well as the reason for the need for confidentiality in a statement to the Editor. The Editor asks each reviewer to disclose any competing interests or conflicts of interest that might interfere with one's objectivity (or to recuse oneself from acting as a reviewer). The Editors and members of the editorial staff have registered their competing interests, if any, with the officers of the American Academy of Dermatology. The Editors and members of the editorial staff will ensure that all conflicts are appropriately resolved. Conflicts that cannot be appropriately resolved will result in rejection of the manuscript or review. Undisclosed conflicts may result in sanctions to include published statements of retraction or removal of a manuscript from the archived journal table of contents and Medline database.

An authorship statement and conflict of interest statement must be submitted with each manuscript. Both forms are included in the January and July issues of the *Journal*.

(see last page of Contents for page number) and are available for download from the JAAD Web site (<http://www.eblue.org>).

**Authorship.** The *Journal's* authorship criteria are adapted from those of the International Committee of Medical Journal Editors and are delineated on the Authorship Statement, which must be signed by each author.

**Role of writers, "ghost writers," and other "third parties" involved in manuscript development and production.** The involvement, nature of involvement, and affiliation or support of any medical writers, "ghost writers," or other individuals or companies or third parties participating in the development or writing of any papers must be noted and explained in the cover letter and in a publishable statement on the manuscript title page. (This does not include tasks such as typing or photocopying.) This statement will be published as part of the first-page footnotes. All individuals involved in the preparation and writing of each paper who meet the JAAD's authorship criteria (see our Authorship Statement) must be listed as authors. The names, highest academic degree, and affiliations of any persons who contributed to writing the paper or analyzing the data who do not meet authorship criteria must be included in the paper's Acknowledgements along with a disclosure of any pertinent conflicts of interest. Individuals listed in the Acknowledgements because of such contributions to the work should provide written consent. The use of "ghost writers" or any author employed by an entity with a commercial interest in any product discussed is rarely appropriate for any manuscript and is strictly prohibited for any CME-accredited activity.

**Special requirements for studies involving live human or animal subjects.** Studies involving live human or animal subjects must have been approved by the authors' Institutional Review Board or its equivalent. A copy of the IRB approval letter must be included with the submission or sent to the *Journal* office under separate cover. If applicable, IRB approval must be mentioned in the methods section of all manuscripts. Patients must not be identified by name or initials; numbers should be used. No other information, including clinical photos or family trees, from which a patient could be identified is permitted unless express written permission from the patient/family is provided at the time of manuscript submission. All clinical investigations must have been conducted according to the Declaration of Helsinki principles. If the Methods section is not sufficiently clear, authors may be asked to provide the editors with a copy of IRB-approved research protocols for the use of our reviewers.

**Special requirements for submission of survey research.** Submissions of survey research must include: 1. A copy of the letter documenting Human Subject Institutional Review Board (IRB) approval. 2. A copy of the survey instrument. (The editors, in consultation with the authors, will determine if the survey instrument should be published and whether it should be published as an online-only Appendix.) The manuscript's Methods section must: 1. Attest that the use of any proprietary sampling contact information (eg, mailing list) was approved by its owner. 2. Provide IRB protocol approval number and date. 3. Describe how the survey instrument was developed and piloted, and whether/how the

survey was validated. During the review process, editors and reviewers may request a copy of the approved study protocol to aid in their evaluation of the study.

**Randomized trials.** Randomized trials must be submitted in a format consistent with the CONSORT statement, along with a completed CONSORT manuscript submission checklist. The word "random" or "randomized" should be in the title. The updated CONSORT guidelines can be accessed by visiting <http://www.consort-statement.org>. A copy of the "CONSORT Checklist for Authors Submitting Reports of Randomized Controlled Trials" may be downloaded from the JAAD Web site (<http://www.eblue.org>).

Any reports of clinical trials submitted after January 1, 2008 must be registered by the time of submission; any study that enrolled the first patient after January 1, 2008 must have been prospectively registered, ie, registered before the first patient was enrolled. The registry must meet ICMJE criteria (available at <http://www.icmje.org>). The registry at <http://www.clinicaltrials.gov> meets such requirements. When submitting a manuscript that reports a clinical trial, authors are asked to provide the date the first patient enrolled, the date the study was registered, and the registration number.

**Priority claims, "firstedness."** Please do not claim that your report is the first reported case. If such a claim is deemed necessary, authors should explain their reasoning in the cover letter and provide a detailed Appendix describing how they came to this conclusion. Describe search strategies, search terms, databases queried, and how far back these were checked. Also list textbooks and monographs that were searched to substantiate the claim.

**Trade names.** Trade names and brand names of drugs and devices may not be used in the title of the paper. They may appear only once in the paper and should be placed in parentheses along with their manufacturer and the manufacturer's location following the first mention of the generic name in the text. Thereafter, only generic names should be used throughout the article.

**On brevity and other matters of style.** Brevity is appreciated. Authors should avoid repeating the same information in the abstract, introduction, and discussion.

**Copyright transfer.** In accordance with the Copyright Act of 1976, which became effective January 1, 1978, the following statement signed by *each* author must accompany the manuscript submitted: "I, the undersigned author, transfer all copyright ownership of the manuscript referenced above to the American Academy of Dermatology, in the event the work is published. I warrant that the article is original, does not infringe upon any copyright or other proprietary right of any third party, is not under consideration by another journal, and has not been published previously. I have reviewed and approve the submitted version of the manuscript and agree to its publication in the *Journal of the American Academy of Dermatology*." A copyright transfer form is included in the January and July issues of the *Journal* (see last page of Contents for page number) and may be downloaded from the JAAD Web site (<http://www.eblue.org>). Author(s) will be consulted, whenever possible, regarding republication of material.

**Special Subject Repositories:** Certain repositories such as PubMed Central ("PMC") are authorized under special

Download English Version:

<https://daneshyari.com/en/article/3207763>

Download Persian Version:

<https://daneshyari.com/article/3207763>

[Daneshyari.com](https://daneshyari.com)